Semaglutide Better Than Liraglutide for Post-Bariatric Surgery Weight Recurrence
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, June 7, 2023 -- Semaglutide is associated with superior weight loss for treating post-metabolic and bariatric surgery (MBS) weight recurrence compared with liraglutide, according to a study published in the May issue of Obesity.
Natia Murvelashvili, M.D., from UT Southwestern Medical Center in Dallas, and colleagues compared the effectiveness of weekly semaglutide versus daily liraglutide for treating post-MBS weight recurrence in a retrospective study. The analysis included 207 adults with post-MBS weight recurrence treated with weekly semaglutide (115 individuals) or daily liraglutide (92 individuals).
The researchers report that the least-squares mean weight change at 12 months was −12.92 percent in the semaglutide group versus −8.77 percent in the liraglutide group. The odds of ≥10 and ≥15 percent weight loss over 12 months were higher in the semaglutide group versus the liraglutide group (adjusted odds ratios, 2.34 and 2.55, respectively). There were no differences seen in the effectiveness of semaglutide versus liraglutide by the subgroups analyzed, including age, sex, and bariatric procedure type.
"A strength of this study is that these real-world data reflect weight-loss outcomes achieved under circumstances of everyday clinical care in a population seeking treatment for post-MBS weight recurrence," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Novo Nordisk, the manufacturer of semaglutide.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Bariatric Surgery Tied to Higher Short-Term Risk for Venous Thromboembolism
THURSDAY, May 9, 2024 -- In the short term, bariatric surgery is associated with a greater risk for venous thromboembolism (VTE), but in the long-term, it is associated with lower...
Endoscopic Sleeve Gastroplasty Is Cost Saving Versus Semaglutide
FRIDAY, April 12, 2024 -- For individuals with class II obesity, endoscopic sleeve gastroplasty (ESG) is cost saving compared with semaglutide, according to a study published...
Bariatric Arterial Embolization Safe, Effective in Patients With Severe Obesity
TUESDAY, April 2, 2024 -- Bariatric arterial embolization (BAE) is feasible, effective, and well tolerated among patients with severe obesity, according to a study presented at...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.